Loading...
Loading...
Sofgen Pharma S.A.
Sofgen Pharma S.A.. Spoken Alpha tracks PROCF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks PROCF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PROCF.
curl https://api.spokenalpha.com/v1/companies/PROCF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.68 | $3.59 | -25.4% | -3.5% | -5.8% |
| Q4 FY2026 | $2.71 | $3.46 | -21.6% | -7.1% | -7.0% |
| Q3 FY2026 | $2.74 | $3.54 | -22.6% | -6.4% | -9.1% |
| Q2 FY2026 | $2.88 | $3.56 | -19.2% | -4.8% | -3.7% |
| Q1 FY2025 | $2.95 | $3.62 | -18.6% | -3.0% | -3.2% |
| Q4 FY2025 | $2.73 | $3.57 | -23.4% | +0.3% | -1.2% |
| Q3 FY2025 | $3.06 | $3.68 | -16.8% | -5.9% | -8.8% |
| Q2 FY2025 | $3.04 | $3.68 | -17.4% | -6.3% | -8.0% |
| Q1 FY2024 | $2.77 | $3.77 | -26.6% | -0.5% | +2.0% |
| Q4 FY2024 | $2.85 | $3.62 | -21.3% | -0.6% | +2.0% |